1. Home
  2. CYTK vs SMTC Comparison

CYTK vs SMTC Comparison

Compare CYTK & SMTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

HOLD

Current Price

$69.27

Market Cap

10.4B

Sector

Health Care

ML Signal

HOLD

Logo Semtech Corporation

SMTC

Semtech Corporation

HOLD

Current Price

$163.64

Market Cap

9.6B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
CYTK
SMTC
Founded
1997
1960
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Semiconductors
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
10.4B
9.6B
IPO Year
2004
2001

Fundamental Metrics

Financial Performance
Metric
CYTK
SMTC
Price
$69.27
$163.64
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
19
15
Target Price
$89.26
$93.20
AVG Volume (30 Days)
1.7M
3.6M
Earning Date
05-05-2026
05-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
79.65
EPS
N/A
0.27
Revenue
$13,368,000.00
$1,049,975,000.00
Revenue This Year
$7.37
$20.10
Revenue Next Year
$310.19
$13.01
P/E Ratio
N/A
$571.41
Revenue Growth
N/A
15.47
52 Week Low
$31.99
$39.07
52 Week High
$80.20
$172.47

Technical Indicators

Market Signals
Indicator
CYTK
SMTC
Relative Strength Index (RSI) 45.21 58.52
Support Level $59.07 $67.57
Resistance Level $70.69 $172.47
Average True Range (ATR) 2.87 14.41
MACD -1.15 -1.91
Stochastic Oscillator 25.26 57.59

Price Performance

Historical Comparison
CYTK
SMTC

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About SMTC Semtech Corporation

Semtech Corp is a provider of high-performance semiconductors powering data center networking, Internet of Things ("IoT") connectivity, and cellular infrastructure solutions. The company designs, develops, manufactures, and markets a diverse portfolio of products for commercial applications, addressing the infrastructure, high-end consumer, and industrial end markets. The company operates in four reportable segments: Signal Integrity, Analog Mixed Signal and Wireless, IoT Systems, and Connected Services. The majority of the company's revenue is earned through the Analog Mixed Signal and Wireless segment. Geographically, the majority of the company's revenue is earned from the Asia Pacific region; the company also operates in North America and Europe.

Share on Social Networks: